Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EBP_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EBP_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EBP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EBP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EBP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EBP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EBP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004586129 | Thyroid | HT | negative regulation of proteolysis | 54/1272 | 351/18723 | 1.31e-08 | 1.08e-06 | 54 |
GO:005086319 | Thyroid | HT | regulation of T cell activation | 51/1272 | 329/18723 | 2.58e-08 | 1.97e-06 | 51 |
GO:002240726 | Thyroid | HT | regulation of cell-cell adhesion | 63/1272 | 448/18723 | 2.83e-08 | 2.07e-06 | 63 |
GO:004361828 | Thyroid | HT | regulation of transcription from RNA polymerase II promoter in response to stress | 16/1272 | 47/18723 | 3.77e-08 | 2.65e-06 | 16 |
GO:004362029 | Thyroid | HT | regulation of DNA-templated transcription in response to stress | 17/1272 | 53/18723 | 3.90e-08 | 2.65e-06 | 17 |
GO:000715920 | Thyroid | HT | leukocyte cell-cell adhesion | 54/1272 | 371/18723 | 8.84e-08 | 5.23e-06 | 54 |
GO:005134628 | Thyroid | HT | negative regulation of hydrolase activity | 54/1272 | 379/18723 | 1.80e-07 | 9.53e-06 | 54 |
GO:003497627 | Thyroid | HT | response to endoplasmic reticulum stress | 41/1272 | 256/18723 | 2.43e-07 | 1.20e-05 | 41 |
GO:190303720 | Thyroid | HT | regulation of leukocyte cell-cell adhesion | 49/1272 | 336/18723 | 3.27e-07 | 1.52e-05 | 49 |
GO:001095126 | Thyroid | HT | negative regulation of endopeptidase activity | 40/1272 | 252/18723 | 4.32e-07 | 1.92e-05 | 40 |
GO:001046627 | Thyroid | HT | negative regulation of peptidase activity | 41/1272 | 262/18723 | 4.59e-07 | 2.02e-05 | 41 |
GO:004211020 | Thyroid | HT | T cell activation | 63/1272 | 487/18723 | 5.95e-07 | 2.51e-05 | 63 |
GO:000181919 | Thyroid | HT | positive regulation of cytokine production | 61/1272 | 467/18723 | 6.46e-07 | 2.68e-05 | 61 |
GO:00507297 | Thyroid | HT | positive regulation of inflammatory response | 26/1272 | 142/18723 | 3.14e-06 | 1.08e-04 | 26 |
GO:00321039 | Thyroid | HT | positive regulation of response to external stimulus | 55/1272 | 427/18723 | 3.50e-06 | 1.16e-04 | 55 |
GO:004212917 | Thyroid | HT | regulation of T cell proliferation | 29/1272 | 171/18723 | 4.30e-06 | 1.39e-04 | 29 |
GO:004209819 | Thyroid | HT | T cell proliferation | 32/1272 | 199/18723 | 4.53e-06 | 1.45e-04 | 32 |
GO:007066110 | Thyroid | HT | leukocyte proliferation | 44/1272 | 318/18723 | 5.29e-06 | 1.64e-04 | 44 |
GO:000762324 | Thyroid | HT | circadian rhythm | 33/1272 | 210/18723 | 5.38e-06 | 1.66e-04 | 33 |
GO:00313497 | Thyroid | HT | positive regulation of defense response | 40/1272 | 278/18723 | 5.40e-06 | 1.66e-04 | 40 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
EBP | SNV | Missense_Mutation | rs782423797 | c.208N>T | p.Ala70Ser | p.A70S | Q15125 | protein_coding | tolerated(0.07) | possibly_damaging(0.489) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-D8-A1X7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | ChemotherapyHormone Therapy | doxorubicine+cyclophosphamide+tamoxifen | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-E9-A1NG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
EBP | SNV | Missense_Mutation | rs782081345 | c.593N>G | p.Val198Gly | p.V198G | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-EW-A1J3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
EBP | deletion | Frame_Shift_Del | novel | c.170delC | p.Pro57HisfsTer22 | p.P57Hfs*22 | Q15125 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
EBP | SNV | Missense_Mutation | rs28935174 | c.440N>A | p.Arg147His | p.R147H | Q15125 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-A6-A56B-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | fluorouracil | PD |